Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Aug 15;6(8):e23522. doi: 10.1371/journal.pone.0023522

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

PMC Copyright notice

In panels A and B, T cells from C57BL/6 wild-type (AhR^+/+) and knockout (AhR^-/-) mice were cultured in the presence of anti-mouse CD3 (2 µg/ml) and CD28 (1 µg/ml) mAbs for 72 hrs. These cells were simultaneously treated with VEH or TCDD (100 nM/ml). The cells were stained for Tregs (CD4⁺ FoxP-3⁺) and Th17 (CD4⁺ IL-17⁺) cells. In panels C and D, C57BL/6 wild type (AhR^+/+) and knockout (AhR^-/-) mice were injected with VEH or TCDD and 5 days later, spleen cells were analyzed for Tregs (CD4⁺ FoxP-3⁺) and Th17 (CD4⁺ IL-17⁺) cells. Both percentages and absolute numbers of Tregs and Th17 cells were depicted. Vertical bars represent data (mean ± SEM) from three independent experiments. Statistical comparisons were made between TCDD and VEH-treated groups and asterisks (*) represent statistically significant (p<0.05) differences.